-
"API + core preparation" walks on both legs West Point Pharmaceuticals landed on the Growth Enterprise Market
Time of Update: 2022-03-07
Market shares of major manufacturers of escitalopram oxalate tablets in my country from 2017 to 2019, source: NMPA Southern InstituteIn the API market field that West Point Pharmaceuticals is involved in, one of the core products - sodium ferulate has a wide range of effects in cardiovascular and cerebrovascular diseases, in the treatment of respiratory diseases, diabetes and its complications, protection of liver and kidneys, etc.
-
With favorable policies, a large number of enterprises in the pharmaceutical supply chain will usher in a period of opportunity
Time of Update: 2022-03-07
Therefore, with the precipitation of technology research and development by Chinese companies over the years, downstream demand is booming, and national policies continue to guide and support, it is expected that some domestic high-end scientific instruments will also accelerate their rise.
-
The centralized procurement of orthopedic consumables is here, and enterprises will enter the "low-price era"
Time of Update: 2022-03-07
For example, a few days ago, Beijing Centralized Pharmaceutical Procurement Service Center, Tianjin Pharmaceutical Procurement Center, and Hebei Provincial Centralized Purchase Center of Medical Drugs and Devices officially announced the "Beijing-Tianjin-Hebei "3+N" Alliance Orthopedic Trauma Medical Consumables with Volume Linked Procurement and Use work plan" .
-
The field of oncology has become a battleground for pharmaceutical companies. What are the future trends?
Time of Update: 2022-03-07
First, Chinese oncology drugs are still dominated by traditional chemical drugs, but from the perspective of the overall research and development trend, targeted drug therapy and immunotherapy are developing rapidly, and the industry expects that they will become an important force in the field of anti-tumor in the future .
-
Under the two major trends, the pharmaceutical equipment industry will usher in new opportunities!
Time of Update: 2022-03-07
The industry expects that with the rapid development of the biopharmaceutical industry and the continuous expansion of enterprise production capacity, the disposable system will gradually replace the traditional stainless steel reactor equipment .
-
In 2022, pharmaceutical companies will accelerate drug review
Time of Update: 2022-03-07
In addition, Chenxin Pharmaceutical has also applied for consistency evaluation of 30 varieties (including the declaration of newly registered generic drugs), of which 10 varieties have been over-evaluated.
-
How well does AI enable small molecule drug discovery?
Time of Update: 2022-03-07
A recent article in Nature Reviews Drug Discovery analyzes the value of AI in the drug discovery process, including its impact on productivity, diversity of molecules discovered, and improvements in clinical success .
-
The national procurement of proprietary Chinese medicines is getting closer and closer, and another major news has just come out
Time of Update: 2022-03-07
For example, Qinghai, Zhejiang Jinhua, Henan Puyang and other places have carried out centralized procurement pilots for some varieties of Chinese patent medicines with large demand and high value in recent years, and achieved certain results .
-
Pfizer's Oral Small Molecule New Coronavirus Treatment Drug Paxlovid Approved in China
Time of Update: 2022-03-07
The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner .
-
17 pharmaceutical companies usher in the first innovative drug, and the new drug may achieve a blowout
Time of Update: 2022-03-07
In September 2021, WuXi Junuo's self-developed Ruiqiorenza injection was approved by the NMPA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after second-line or above systemic therapy.
-
These two pharmaceutical companies have joined forces to launch new anti-tumor drug commercialization cooperation!
Time of Update: 2022-03-07
Just recently, Baheal Pharma announced that it will "join hands" with Shanghai Yizhong, and the two sides will cooperate on the commercialization of Zisheng, an innovative tumor drug under Shanghai Yizhong, "Paclitaxel Polymeric Micellar for Injection" ("Paclitaxel Micellar" for short) .
Zisheng®, the "paclitaxel polymer micelle for injection" independently developed by Shanghai Yizhong, is a new dosage form of 2.
-
4 pharmaceutical companies expect net profit to increase by over 1000% in 2021
Time of Update: 2022-03-07
8% Lisheng Pharmaceutical disclosed the performance forecast on the evening of January 21, saying that the net profit in 2021 is expected to be 110 million-140 million yuan, a year-on-year increase of 1176.
-
FDA Accepts Precision Therapeutics New Drug Application for Certain Non-Small Cell Lung Cancers
Time of Update: 2022-03-07
S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for poziotinib, a tyrosine kinase inhibitor (TKI), for the treatment of previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations .
-
The market of traditional Chinese medicine formula granules is expected to exceed 150 billion, and many pharmaceutical companies are accelerating their deployment
Time of Update: 2022-03-07
In addition, according to relevant regulations, manufacturers of traditional Chinese medicine formula granules should have complete production capacity such as processing, extraction, concentration, drying, and granulation of decoction pieces, formulate detailed production processes and standard operating procedures for each variety, and strictly implement drug production quality management.
-
The number of innovative traditional Chinese medicine drugs is growing "blowout", this field may benefit
Time of Update: 2022-03-07
With the rapid development of the traditional Chinese medicine industry and the continuous approval of innovative traditional Chinese medicine drugs, the traditional Chinese medicine extraction equipment industry is expected to gain opportunities .
-
The 8MW2311 immune agonist of Maiwei Bio-Injection was approved for clinical use
Time of Update: 2022-03-07
received the "Notice of Acceptance" approved and issued by the State Drug Administration, and the clinical trial application of 8MW2311 for injection was accepted .
8MW2311 for injection is a polyethylene glycol conjugated human interleukin-2 immune agonist for the treatment of advanced malignant tumors .
-
What's behind the NMPA's emergency approval of Pfizer's new coronavirus drug import?
Time of Update: 2022-03-07
On February 12, 2022, the State Food and Drug Administration announced that Pfizer's new coronavirus treatment drug nematevir tablet/ritonavir tablet combination package import registration has been approved with emergency conditions .
-
The first CD19-targeted ADC therapy launched Phase 3 clinical joint development supported by Hillhouse
Time of Update: 2022-03-07
According to public information, Lonca, developed by ADC Therapeutics, is the first FDA-approved antibody-drug conjugate targeting CD19, which can be used as a single agent for the treatment of adult patients with relapsed/refractory large B-cell lymphoma .
-
The reform of medical insurance payment is accelerated, and many provinces issue action plans
Time of Update: 2022-03-07
By the end of 2022, the province's 17 co-ordination areas will comprehensively carry out the DRG/DIP payment method reform to achieve full coverage in the co-ordination areas; by the end of 2023, all co-ordination areas will basically achieve full coverage of eligible medical institutions, diseases, and medical insurance funds; by the end of 2024, basically Establish a new medical insurance payment mechanism that is unified across the province, linked up and down, coordinated internally and externally, standardized, and efficient .
-
There are frequent changes in the executives of domestic and foreign pharmaceutical companies, and the battle for talent will start
Time of Update: 2022-03-07
Chen Guang, the current head of the parenteral nutrition and anesthesia division, will be promoted to the executive deputy general manager of Fresenius Kabi Huarui Pharmaceuticals.
